Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

on. Patients who achieved a partial response, or had stable disease lasting through Week 52, were eligible for re-treatment, a booster, using the same protocol and dose as the initial treatment. Endpoints included safety, immunologic activity and antitumor activity.

Study Results

Treatment with NEUVENGE was generally well tolerated. The majority of side effects were mild, including infusion-related fever and chills that were usually of low grade and typically lasted for one to two days following infusion. No patient discontinued the trial because of toxicity.

Treatment with NEUVENGE stimulated significant immune responses, which were shown to be enhanced following booster infusions. Twenty-two percent of patients had evidence of anti-cancer activity. This included one patient who experienced a partial response lasting approximately 6 months and three patients who had stable disease for over a year (74.9-94.0 weeks) without the addition of any other cancer therapy other than the continuation of bisphonates. Two additional patients had stable disease for up to 20 weeks. The study concluded that NEUVENGE was feasible, well-tolerated and showed evidence of anti-cancer activity.

"We are pleased that the results from this Phase I study of NEUVENGE demonstrate its potential as a treatment for advanced breast cancer patients," said Mark Frohlich, M.D., vice president of clinical affairs at Dendreon. "These data, together with the data we have published on the use of Provenge(R) (sipuleucel-T) in prostate cancer, further substantiate the promise of active cellular immunotherapies as new treatments for different types of cancer."

About NEUVENGE

NEUVENGE (lapuleucel-T) is an investigational product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. ACIs hold promise because they may provide patients with a meaningful clinical benefit with low toxicities. NEUVENGE is
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
(Date:7/30/2015)... 30, 2015 P&S ... with market overview, trends, DRO analysis, market ... recent developments, competitive scenario and top competitor ... Biosensors Market Development and Demand Forecast to ... ) Explore more about global ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
(Date:7/31/2015)... ... 2015 , ... Ticket Down is a reliable source for authentic tickets for ... Park. The festival will end on Sunday, August 2nd. , Music ... Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment from ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... new store run by GoodThreads. The store can be accessed by visiting ... many of which are customizable. The best part: whenever a product is purchased, ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... There’s ... as possible, even when it comes time to cook the next meal, making July ... of July by practicing best grilling tips and recipes. , Make the next cookout ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...
(Date:7/31/2015)... ... ... the article published July 27 on My News LA, a fire that broke ... city’s fire department before it caused major damage throughout the building. The article also notes ... was a fire alarm system that tipped off fire fighters so they could arrive at ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... America, Inc. has donated a new 2009 Subaru Outback ... Southern New Jersey, located in Camden. The All-Wheel ... to transport RMH families of children being treated for ... be used by RMH staff to support day-to-day operations ...
... Scientists found levels of certain cytokines spiked during disease ... in South Africa recently had the rare opportunity to ... symptoms and recovery in a 29-year-old lab worker who ... In particular, the researchers followed the trajectory of cytokines, ...
... needs of a child dependent on technology is a daunting ... to help everyone in the family adjust. However, mothers often ... of raising these children, a research study from Case Western ... from me," one mother told Valerie Toly, PhD, R.N., C.P.N.P., ...
... March 18 Cogdell Spencer Inc. (NYSE: ... has declared a quarterly dividend of $0.225 per common share ... March 31, 2009. The dividend covers the first quarter ... Cogdell Spencer Inc. (NYSE: CSA ) is a ...
... Survey shows they suffer consequences of delaying doctor visits, ... Millions of Americans suffering from at least one chronic ... medications, and resigning themselves to feelings of isolation and ... commissioned by the National Council on Aging, with support ...
... Concerns still persist within the general clinical community regarding ... the use of analgesics such as the nonsteroidal anti-inflammatory ... inhibitor NSAIDs continues to raise the concern of cardio-renal ... physicians but also in the perception of many patients ...
Cached Medicine News:Health News:Subaru of America Donates New Outback to Aid Ronald McDonald House Families 2Health News:Subaru of America Donates New Outback to Aid Ronald McDonald House Families 3Health News:Course of West Nile Infection Charted 2Health News:Course of West Nile Infection Charted 3Health News:Mothers have key role in family life for children with technology dependencies 2Health News:Cogdell Spencer Inc. Declares Quarterly Dividend 2Health News:Millions of Americans With Chronic Ills Put Off Health Care 2Health News:Millions of Americans With Chronic Ills Put Off Health Care 3Health News:Millions of Americans With Chronic Ills Put Off Health Care 4Health News:CMEFirst Presents State-of-the-Art Arthritis CME Symposium 2Health News:CMEFirst Presents State-of-the-Art Arthritis CME Symposium 3Health News:CMEFirst Presents State-of-the-Art Arthritis CME Symposium 4
... many patients with a diseased heart, the only therapy ... heart transplant. However, donor organs are not always readily ... they are on the waiting list for a donor ... can save the life of a patient. On the ...
... InstaTest AFP is an immunochromatographic in ... protein (AFP) in human serum. AFP is ... 67,000 to 74,000 D. Its normal concentration ... concentrations are associated with hepatoma and ovarian, ...
... STA Compact is a ... coagulation analyser for clotting, ... based .coagulation tests.The medium-throughput ... of primary tubes, 45 ...
... Our high-quality MPD Lancets are designed with ... the tri-bevel, thin gauge needle with its ... smoother, less painful penetration without tearing the ... body is easy to grip, even for ...
Medicine Products: